Myriad genetics®

Third Quarter 2026 Earnings Call

November 4, 2026



©2026 Myriad Genetics, Inc.

Forward-looking statements and Non-GAAP financial measures

Some of the information presented here today contains projections or other forward-looking statements regarding future events or the future financial performance of the Company.

FORWARD-LOOKING STATEMENTS AND DISCLAIMERS

These statements are based on management's current expectations and the actual events or results may differ materially and adversely from these expectations. We refer you to the documents the Company files from time to time with the Securities and Exchange Commission, specifically, the Company's annual report on Form 10-K, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in the Company's projections or other forward-looking statements. The Company is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.

All third-party marks—® and ™—are the property of their respective owners. Certain market and industry data has been obtained from third-party sources, which the Company believes are reliable, but the Company has not independently verified the information provided by third-party sources. Unless otherwise noted, market growth rates used in this presentation are estimates based on Company and third-party industry research.

NON-GAAP FINANCIAL MEASURES

In this presentation, the Company's financial results and financial guidance are provided in accordance with accounting principles generally accepted in the United States (GAAP) and using certain non-GAAP financial measures. Management believes that presentation of operating results using non-GAAP financial measures provides useful supplemental information to investors and facilitates the analysis of the Company's core operating results and comparison of operating results across reporting periods. Management also uses non-GAAP financial measures to establish budgets and to manage the Company's business. Definitions of the non-GAAP financial measures and a reconciliation of the GAAP to non-GAAP financial results are provided in the Appendix to this presentation.

The Company does not provide forward-looking guidance on a GAAP basis for the measures on which it provides forward-looking non-GAAP guidance as the Company is unable to provide a quantitative reconciliation of forward-looking non-GAAP measures to the most directly comparable forward-looking GAAP measure, without unreasonable effort, because of the inherent difficulty in accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliations that have not yet occurred, are dependent on various factors, are out of the Company's control, or cannot be reasonably predicted at the time of this presentation. Such adjustments include, but are not limited to, strategic realignment, costs related to amortization of intangibles from acquisitions, impairment and related charges, depreciation, equity compensation, tax benefits, and other adjustments. For example, stock-based compensation may fluctuate based on the timing of employee stock transactions and unpredictable fluctuations in the Company's stock price. Any associated estimate of these items and their impact on GAAP performance could vary materially.

©2026 Myriad Genetics, Inc.

Progress

Sam Raha

PRESIDENT AND
CHIEF EXECUTIVE OFFICER

©2026 Myriad Genetics, Inc.

Third quarter 2026 performance and takeaways

Q3'26 revenue benefits from CCC mix & avg revenue per test

Q3‘26 revenue of $202.7M reflects YOY volume changes in:

- Cancer Care Continuum: 4%
- Mental Health: 3%
- Prenatal Health: (11)%

YOY changes in average revenue per test of:

- Cancer Care Continuum: (3)%
- Mental Health: (1)%
- Prenatal Health: (1)%

Q3'26 profitability improves from Q2'26

67.9% gross margins in Q3‘26; 130 basis points higher than Q2'26

$(5.3M) adj EBITDA* and $(0.11) adj EPS* in Q3’26 vs. $(16.9M) adj EBITDA and $(0.25) adj EPS in Q2’26

Solid liquidity position; Access to ~$182M at end of Q3’26

Sale of Prenatal business to unlock significant value

Announced sale of Prenatal business to Labcorp (10/20)

- $210M + inventory, all-cash
- Expected to be accretive to revenue growth and profitability
- Target close by early 2027

Raising mid-point of 2026 revenue guidance to reflect positive Q3'26 progress and current outlook

*GAAP to non-GAAP reconciliations for Q3‘26 can be found in the Appendix.

©2026 Myriad Genetics, Inc.

Prenatal Health: Unlocking potential value through announced divestiture



Deal rationale and expected benefits

1. Improves Myriad's liquidity, accretive to revenue growth/profitability
2. Maximizes benefits for patients, clinicians, employees and shareholders
3. Enables increased focus on the Cancer Care Continuum market opportunity

MYRIAD PRENATAL HEALTH BUSINESS*

Tests Reported (K):	Revenue ($M):	Gross Margin:
~600	**$165**	**~40%**

** Last Twelve Months as of September 30, 2026.*

©2026 Myriad Genetics, Inc.

Third Quarter 2026 Business Update

©2026 Myriad Genetics, Inc.

CANCER CARE CONTINUUM

Continuing Hereditary Cancer Test volume growth; Progressing MRD



Third quarter 2026 and recent highlights

- Another record high volume quarter for unaffected HCT in last three years
- Continued expansion of hereditary cancer testing guidelines
- Precise MRD early access testing continues; await reimbursement coverage (MolDX on-track); positive user feedback
- In October 2026, Precise MRD CRC data from MONSTAR3 study presented at European Society of Medical Oncology (ESMO)

Operational results:

$124M
Q3‘26 revenue

~98K
Q3‘26 test volume

Key performance indicators:

Hereditary Cancer

6%
Volume growth[1]

(1)%
Revenue growth[1]

1: Q3‘26 Growth YOY

©2026 Myriad Genetics, Inc.

MENTAL HEALTH

Maintaining leadership with disciplined level of investment and focus



Third quarter 2026 and recent highlights

- Q3’26 GeneSight revenue increased 2% YOY, reflecting a (1)% YOY change in average revenue per test
- 40K+ clinicians ordered GeneSight in Q3’26
- Maintaining focus on expanding coverage and go-to-market strategies

Operational results:

$40M
Q3‘26 revenue

~141K
Q3‘26 test volume

Key performance indicators:

GeneSight

3%
Volume growth[1]

2%
Revenue growth[1]

1: Q3‘26 Growth YOY

©2026 Myriad Genetics, Inc.

Announced Prenatal Health divestiture: positive for stakeholders



Third quarter 2026 and recent highlights

- October 20 announced definitive agreement to sell Prenatal Health test business to Labcorp; target close by early 2027

SEE PRESS RELEASE >

Operational results:

$39M
Q3‘26 revenue

~138K
Q3‘26 test volume

Key business indicators:

Prenatal

(11)%
Volume growth[1]

(12)%
Revenue growth[1]

1: Q3‘26 Growth YOY

©2026 Myriad Genetics, Inc.

On-track with key 2026 product publications, submissions and launches

HCT

- Launched MyRisk Disease Specific Panels; H1‘26
- Increase sample volume growth rate

Prostate Cancer

- Launched Prolaris + AI test; Q2’26
- Prolaris meta-analysis publication published; July’26

Precise MRD

- Initiated commercial testing for select customers; March‘26
- MolDX submission for Breast; July'26
- Breast publication; MONITOR study published; Q2’26
- MolDx submissions for Renal and CRC; H1’27E
- CRC data publication, MONSTAR3 study; H2’26E

Prenatal Health

- Reported out on FirstGene CONNECTOR study; H1‘26
- Commercial launch of FirstGene; July'26

Cancer Care Continuum

- Focus on increasing sample volume growth
- Expect to add new strategic partnerships as part of growth plan

©2026 Myriad Genetics, Inc.

Financial Update

Ben Wheeler

CHIEF FINANCIAL OFFICER

©2026 Myriad Genetics, Inc.

Third quarter 2026 performance

Demonstrating progress with multiple initiatives, including revenue cycle management

- Q3'26 revenue benefits from mix, average test revenue
- Average revenue per test improved in Q3’26 YOY
- Positive demand in CCC continues
- Sale of Prenatal Health business expected to enhance financial profile
- Ascend initiative-related actions

A Look at Myriad Post Sale


- Positioned for higher revenue growth and profitability
- Focused on Cancer Care Continuum
- Simplified operations

©2026 Myriad Genetics, Inc.

Recent initiatives contribute to improving Q3’26 average revenue per test

Hereditary Cancer Test (HCT)

9% Change in average revenue per test in Q3’26 over Q2’26



Key takeaways:

- Q3’26 average revenue per HCT declined 6% YOY but improved 9% compared to Q2’26 reflecting traction with recent initiatives
- $1,000 - $1,200 range of average revenue per HCT test (Q3’25 – Q3’26)
- Prior-period collection adjustments were immaterial in Q3’26 and Q3’25, but reduced Q2’26 revenue by $11 million

Comprehensive action plan

RCM improvements

Optimizing workflows to accelerate cash collections and improve predictability

Team investments

Building on past investments in team capabilities and tools to increase precision in claim processing

Ongoing third party engagement

Advancing reimbursement stability through payer engagement, LBM collaboration, and policy advocacy

©2026 Myriad Genetics, Inc.

Continued strong gross profit and healthy liquidity position

Gross Profit
Generated approximately
$138M
in Q3‘26

Adj EBITDA[1]
Generated a loss of
$5M
in Q3‘26

Liquidity position[2]
Access to
~$182M
As of September 30, 2026

Additional highlights:

Sale of Prenatal Health business expected to add ~$200M cash

Generated adj operating cash flow[1] of $4M; adj free cash flow[1] of $2M in Q3’26

1 GAAP to non-GAAP reconciliations can be found in the Appendix
2 Consists of $107 million of cash and cash equivalents and availability of additional $75 million under term loan facility

©2026 Myriad Genetics, Inc.

Prenatal Health divestiture expected to be a catalyst for unlocking value

Myriad genetics® | labcorp

P&L impact and guidance considerations

Prenatal Health generated revenue of $165M*; gross margins of ~40%*

Potential Benefits

(first 12-months post close):

revenue growth: (YOY) **100+** basis points

gross margins: **500+** basis points

Transaction details

- $210M + inventory all cash deal; 1.3x revenue*
- Deal includes all related tests, test inventory, multiple CA-based facilities and human capital
- Expect to close by early 2027; Until then, Prenatal Health business will continue to operate as part of Myriad Genetics (included in 2026 financial guidance)

Potential use of proceeds

- Debt reduction
- Growth investments
- General corporate purposes

**Trailing twelve months as of September 30, 2026*

©2026 Myriad Genetics, Inc.

Raising mid-point of full year 2026 revenue guidance range

All figures in millions, except percentages

UPDATED 2026 REVENUE GUIDANCE

$780 - $790M

Previous **$770 - $790M**

CCC + Mental Health	Prenatal Health
$620M – $630M	**~$160M**

Adjusted gross margin* unchanged at **66% - 67%**

Guidance reflects positive CCC and Mental Health current business trends partially offset by Prenatal Health divestiture dynamics

*The company does not forecast GAAP gross margin, because it cannot predict certain elements that are included in reported GAAP results. See the statement on Non-GAAP Financial Measures at the beginning of this presentation and the Appendix to this presentation for more information about the use of non-GAAP financial measures.

Assumes currency rates as of November 4, 2026.

©2026 Myriad Genetics, Inc.

Closing Comments

Sam Raha

PRESIDENT &
CHIEF EXECUTIVE OFFICER

©2026 Myriad Genetics, Inc.

Taking important actions to better position Myriad to drive accelerated profitable growth

STRATEGIC ACTIONS

- Divest Prenatal Health business
- Mitigate payer friction
- Increase org efficiency, productivity, and scalability

STRENGTHEN

- Financial profile
- Predictability
- Focus on the cancer care continuum



©2026 Myriad Genetics, Inc.

Q&A

©2026 Myriad Genetics, Inc.

Appendix

©2026 Myriad Genetics, Inc.

Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Nine Months Ended September 30, 2026 and 2025 – Adjusted Gross Margin

(unaudited data in millions)

	Three months ended September 30,		Nine months ended September 30,	
	2026	2025	2026	2025
Adjusted Gross Margin				
Gross Profit	$ 137.7	$ 143.8	$ 402.3	$ 429.8
Acquisition - amortization of intangible assets[1]	—	—	0.1	0.6
Equity compensation[2]	0.2	0.3	0.9	0.9
Strategic realignment[3]	0.4	—	0.4	—
Other adjustments[4]	—	—	—	0.3
Adjusted Gross Profit	$ 138.3	$ 144.1	$ 403.7	$ 431.6
Adjusted Gross Margin	68.2 %	70.1 %	68.0 %	70.2 %

(1) Represents recurring amortization charges resulting from the acquisition of intangible assets.

(2) Consists of the non-cash equity-based compensation provided to Myriad Genetics employees.

(3) Costs related to strategic realignment of the company including severance and consulting fees.

(4) Other one-time non-recurring adjustments.

©2026 Myriad Genetics, Inc.

Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Nine Months Ended September 30, 2026 and 2025 – Adjusted Operating Expenses

(unaudited data in millions)

	Three months ended September 30,		Nine months ended September 30,	
	2026	2025	2026	2025
Adjusted Operating Expenses				
Operating Expenses	$ 177.6	$ 167.1	$ 511.8	$ 811.3
Acquisition - amortization of intangible assets[1]	(6.5)	(6.5)	(19.3)	(23.4)
Goodwill and long-lived asset impairment[2]	—	—	(5.4)	(316.7)
Equity compensation[3]	(9.0)	(11.9)	(22.0)	(31.5)
Real estate optimization[4]	—	—	—	(5.2)
Strategic realignment[5]	(12.2)	(8.3)	(16.2)	(10.1)
Other adjustments[6]	—	(0.4)	—	—
Adjusted Operating Expenses	$ 149.9	$ 140.0	$ 448.9	$ 424.4

©2026 Myriad Genetics, Inc.

Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Nine Months Ended September 30, 2026 and 2025 – Adjusted Operating Expenses (Cont.)

(1) Represents recurring amortization charges resulting from the acquisition of intangible assets.

(2) Expense related to goodwill and long-lived asset impairment. For the nine months ended September 30, 2026, consists of $5.4 million of impairment expense associated with our Women's Health reporting unit and certain intangible assets. For the nine months ended September 30, 2025, consists of $316.7 million of impairment expense associated with our Mental Health and Women's Health reporting units and asset groups.

(3) Consists of the non-cash equity-based compensation provided to Myriad Genetics employees and directors.

(4) Costs related to real estate initiatives. For the nine months ended September 30, 2025, consists of additional rent as a result of the build-out of our new laboratories in Salt Lake City, Utah and South San Francisco, California, while maintaining our then existing laboratories in those locations and testing and set-up costs for equipment in our new facilities.

(5) Costs related to strategic realignment of the company including severance and consulting fees.

(6) Other one-time non-recurring adjustments.

©2026 Myriad Genetics, Inc.

Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Nine Months Ended September 30, 2026 and 2025 – Adjusted Net Income (Loss)

(unaudited data in millions, except per share amounts)

	Three months ended September 30,		Nine months ended September 30,	
	2026	2025	2026	2025
Adjusted Net Income (Loss)[1]				
Net Loss	$ (43.9)	$ (27.4)	$(121.2)	$(358.0)
Acquisition - amortization of intangible assets[2]	6.5	6.5	19.4	24.0
Goodwill and long-lived asset impairment[3]	—	—	5.4	316.7
Equity compensation[4]	9.2	12.2	22.9	32.4
Real estate optimization[5]	—	—	—	5.2
Strategic realignment[6]	12.6	8.3	16.6	10.1
Other adjustments[7]	—	0.4	—	0.4
Uncertain tax benefit[8]	—	—	—	(29.0)
Tax adjustments[9]	4.9	0.2	14.6	0.1
Adjusted Net Income (Loss)	$ (10.7)	$ 0.2	$ (42.3)	$ 1.9
Weighted average shares outstanding:				
Diluted	95.7	93.8	94.7	93.2
Adjusted Income (Loss) Per Share				
Diluted	$ (0.11)	$ —	$ (0.45)	$ 0.02

©2026 Myriad Genetics, Inc.

Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Nine Months Ended September 30, 2026 and 2025– Adjusted Net Income (Loss) (Cont.)

(1) To determine Adjusted Income (Loss) Per Share.

(2) Represents recurring amortization charges resulting from the acquisition of intangible assets.

(3) Expense related to goodwill and long-lived asset impairment. For the nine months ended September 30, 2026, consists of $5.4 million of impairment expense associated with our Women's Health reporting unit and certain intangible assets. For the nine months ended September 30, 2025, consists of $316.7 million of impairment expense associated with our Mental Health and Women's Health reporting units and asset groups.

(4) Consists of the non-cash equity-based compensation provided to Myriad Genetics employees and directors.

(5) Costs related to real estate initiatives. For the nine months ended September 30, 2025, consists of additional rent as a result of the build-out of our new laboratories in Salt Lake City, Utah and South San Francisco, California, while maintaining our then existing laboratories in those locations and testing and set-up costs for equipment in our new facilities.

(6) Costs related to strategic realignment of the company including severance and consulting fees.

(7) Other one-time non-recurring adjustments.

(8) Consists of the release of unrecognized tax benefits and the recognition of valuation allowances for the nine months ended September 30, 2025. The unrecognized tax benefits released were primarily related to tax years under Joint Committee on Taxation review, which upon conclusion of the review were remeasured or released.

(9) Tax expense or benefit due to non-GAAP adjustments, differences between stock compensation recorded for book purposes as compared to the allowable tax deductions, and valuation allowance recognized against federal and state deferred tax assets in the United States. As of September 30, 2026, a valuation allowance of $129.1 million was not recognized for non-GAAP purposes given our historical and forecasted positive earnings performance. As of September 30, 2025, a valuation allowance of $104.8 million was not recognized for non-GAAP purposes given the company's historical and forecasted positive earnings performance.

©2026 Myriad Genetics, Inc.

Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Nine Months Ended September 30, 2026 and 2025 – Adjusted EBITDA

(unaudited data in millions)

	Three months ended September 30,		Nine months ended September 30,	
	2026	2025	2026	2025
Adjusted EBITDA				
Net Loss	$ (43.9)	$ (27.4)	$ (121.2)	$ (358.0)
Acquisition - amortization of intangible assets[1]	6.5	6.5	19.4	24.0
Depreciation expense[2]	4.9	4.8	14.4	14.8
Goodwill and long-lived asset impairment[3]	—	—	5.4	316.7
Equity compensation[4]	9.2	12.2	22.9	32.4
Real estate optimization[5]	—	—	—	5.2
Strategic realignment[6]	12.6	8.3	16.6	10.1
Interest expense, net of interest income[7]	3.5	3.3	10.6	5.1
Other adjustments[8]	1.6	1.4	4.3	2.5
Uncertain tax benefits[9]	—	—	—	(29.0)
Income tax expense[10]	0.3	1.2	0.9	0.8
Adjusted EBITDA	$ (5.3)	$ 10.3	$ (26.7)	$ 24.6

©2026 Myriad Genetics, Inc.

Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Nine Months Ended September 30, 2026 and 2025 – Adjusted EBITDA (Cont.)

(1) Represents recurring amortization charges resulting from the acquisition of intangible assets.

(2) Consists of depreciation expense recognized during the period.

(3) Expense related to goodwill and long-lived asset impairment. For the nine months ended September 30, 2026, consists of $5.4 million of impairment expense associated with our Women's Health reporting unit and certain intangible assets. For the nine months ended September 30, 2025, consists of $316.7 million of impairment expense associated with our Mental Health and Women's Health reporting units and asset groups.

(4) Consists of the non-cash equity-based compensation provided to Myriad Genetics employees and directors.

(5) Costs related to real estate initiatives. For the nine months ended September 30, 2025, consists of additional rent as a result of the build-out of our new laboratories in Salt Lake City, Utah and South San Francisco, California, while maintaining our then existing laboratories in those locations and testing and set-up costs for equipment in our new facilities.

(6) Costs related to strategic realignment of the company including severance and consulting fees.

(7) Derived from interest expense and interest income from the Condensed Consolidated Statements of Operations.

(8) Other one-time non-recurring expenses. For purposes of adjusted EBITDA, this includes Other adjustments described in the Adjusted Net Income (Loss) table above as well as the amounts reported as Other income (expense) in the Condensed Consolidated Statement of Operations.

(9) Consists of the release of unrecognized tax benefits and the recognition of valuation allowances for the nine months ended September 30, 2025. The unrecognized tax benefits released were primarily related to tax years under Joint Committee on Taxation review, which upon conclusion of the review were remeasured or released.

(10) Derived from Income tax expense (benefit) from the Condensed Consolidated Statement of Operations, net of the adjustment for unrecognized tax benefits described in Note 9 above.

©2026 Myriad Genetics, Inc.

Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Nine Months Ended September 30, 2026 and 2025 – Adjusted Free Cash Flow

(unaudited data in millions)

	Three months ended September 30,		Nine months ended September 30,	
	2026	2025	2026	2025
Adjusted Operating and Free Cash Flow				
Net Cash Provided by (Used in) Operating Activities	$ (6.5)	$ 21.1	$ (30.5)	$ (8.8)
Real estate optimization[1]	—	1.2	—	8.7
Strategic realignment[2]	10.2	2.3	13.1	4.1
Other adjustments[3]	—	0.2	—	0.2
Adjusted Operating Cash Flow	$ 3.7	$ 24.8	$ (17.4)	$ 4.2
Capital expenditures[4]	(1.8)	(2.8)	(9.3)	(10.9)
Capitalization of internal-use software costs[4]	(0.3)	(3.4)	(2.5)	(10.5)
Adjusted Free Cash Flow	$ 1.6	$ 18.6	$ (29.2)	$ (17.2)

(1) The cash flow effect of real estate optimizations, excluding non-cash items such as accelerated depreciation.

(2) Strategic realignment includes the cash paid for severance and consulting fees.

(3) The cash flow effect of other one-time non-recurring expenses.

(4) Derived from the Condensed Consolidated Statements of Cash Flows.

©2026 Myriad Genetics, Inc.